TY - JOUR
T1 - Reappraisal of β-blocker therapy in the acute and chronic post-myocardial infarction period
AU - Borrello, Francesco
AU - Beahan, Maribeth
AU - Klein, Liviu
AU - Gheorghiade, Mihai
PY - 2003
Y1 - 2003
N2 - In patients presenting with acute myocardial infarction (MI), the early use of intravenous β-blockade followed by short-term oral administration in the absence of reperfusion therapy has shown a modest reduction in mortality. In contrast, major reductions in mortality and reinfarction have been shown when β-blockers have been used soon after an acute MI and continued long-term. These benefits were observed in trials conducted in the 1970s and 1980s, prior to the widespread use of reperfusion therapies, antiplatelet agents, and angiotensin-converting enzyme inhibitors; those trials excluded patients with postischemic heart failure. Recently, the CAPRICORN trial has shown a significant reduction in all-cause mortality and reinfarction in post-MI patients with systolic dysfunction, in response to carvedilol. In spite of compelling evidence supporting the use of β-blockers in the post-MI setting, data published by the National Cooperative Cardiovascular Project have shown that fewer than half of all post-MI patients receive β-blockers as long-term therapy. It appears that post-MI patients with perceived contraindications, such as advanced age, diabetes, heart failure, peripheral vascular disease, and/or chronic pulmonary obstructive disease, may derive a substantial benefit from the use of β-blockers. Given the considerable evidence from randomized clinical trials, the use of β-blockers is recommended in all post-MI patients without a contraindication, particularly in those with left ventricular systolic dysfunction.
AB - In patients presenting with acute myocardial infarction (MI), the early use of intravenous β-blockade followed by short-term oral administration in the absence of reperfusion therapy has shown a modest reduction in mortality. In contrast, major reductions in mortality and reinfarction have been shown when β-blockers have been used soon after an acute MI and continued long-term. These benefits were observed in trials conducted in the 1970s and 1980s, prior to the widespread use of reperfusion therapies, antiplatelet agents, and angiotensin-converting enzyme inhibitors; those trials excluded patients with postischemic heart failure. Recently, the CAPRICORN trial has shown a significant reduction in all-cause mortality and reinfarction in post-MI patients with systolic dysfunction, in response to carvedilol. In spite of compelling evidence supporting the use of β-blockers in the post-MI setting, data published by the National Cooperative Cardiovascular Project have shown that fewer than half of all post-MI patients receive β-blockers as long-term therapy. It appears that post-MI patients with perceived contraindications, such as advanced age, diabetes, heart failure, peripheral vascular disease, and/or chronic pulmonary obstructive disease, may derive a substantial benefit from the use of β-blockers. Given the considerable evidence from randomized clinical trials, the use of β-blockers is recommended in all post-MI patients without a contraindication, particularly in those with left ventricular systolic dysfunction.
KW - Myocardial infarction
KW - Β-Blocker
UR - http://www.scopus.com/inward/record.url?scp=0141505928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141505928&partnerID=8YFLogxK
M3 - Article
C2 - 14564230
AN - SCOPUS:0141505928
SN - 1530-6550
VL - 4
SP - S13-S24
JO - Reviews in Cardiovascular Medicine
JF - Reviews in Cardiovascular Medicine
IS - SUPPL. 3
ER -